Revenue Growth (Quarterly) score
Year-over-year revenue growth for each of the last four quarters, weighted toward the latest. Higher is better, judged against the company's sector range.
How StocksScores scores it
Each quarter's revenue is compared with the same quarter one year earlier (not the previous quarter), each change capped between -100% and +300%. The last four of these year-over-year rates are averaged with more weight on recent quarters (weights 1, 2, 3, 4). Scored against a sector band where higher is better: a value at the band's floor scores about 35, at its ceiling about 95, linear in between; half a band-width below the floor scores about 5, and beyond either end the score keeps easing toward 0 or 100 instead of clipping. The band is picked by industry first (consumer electronics, semiconductors, grocery and discount retail have their own), then by sector, else a general default. The quarterly version widens the band by multiplying the sector floor by 0.75 and the ceiling by 1.25; with the default band (-2% to 20%) that means 0% growth scores about 38 and 25% growth about 95. For banks, whose statements carry no revenue line, revenue is taken as net interest income plus non-interest income.
Data: Quarterly income statements from Finnhub (revenue per quarter; the fetch keeps the most recent 8 to 16 quarters).
Not scored when: Fewer than five quarters with positive revenue, so no year-over-year comparison exists.
Weight in the stock score
It carries 5% of the fundamental pillar's weight (4 of 84). The fundamental total is then ranked within the company's sector, and that pillar is 80% of the composite score.
The full method — timeframes, the sector ranking and how missing data is handled — is on how the stock score works. For the metric itself, read Growth Investing: How to Identify High-Growth Stocks Early.
Revenue Growth (Quarterly) across US stocks today
2,287 US companies worth $1B or more have a Revenue Growth (Quarterly) reading as of Nov 19, 2026; the median scores 57.
- Bearish · 0–39
- 409
- Weak · 40–49
- 442
- Neutral · 50–65
- 574
- Bullish · 66–79
- 279
- Very bullish · 80–100
- 583
Median by sector
| Sector | Stocks | Median |
|---|---|---|
| Utilities | 75 | 84 |
| Energy | 146 | 68 |
| Industrials | 311 | 65 |
| Basic Materials | 119 | 64 |
| Financial Services | 412 | 63 |
| Real Estate | 119 | 62 |
| Communication Services | 102 | 54 |
| Healthcare | 294 | 53 |
| Consumer Defensive | 103 | 52 |
| Consumer Cyclical | 251 | 52 |
| Technology | 355 | 44 |
Highest Revenue Growth (Quarterly) scores
| Company | Sector | Market cap | Score |
|---|---|---|---|
| MU Micron Technology | Technology | $781.2B | 100 |
| SNDK Sandisk | Technology | $107.5B | 100 |
| CEG Constellation Energy | Utilities | $88.6B | 100 |
| BAM Brookfield Asset Management | Financial Services | $80.2B | 100 |
| BE Bloom Energy | Industrials | $49.7B | 100 |
| KDP Keurig Dr Pepper | Consumer Defensive | $48.8B | 100 |
| RKT Rocket Companies | Financial Services | $37.4B | 100 |
| HSY The Hershey Company | Consumer Defensive | $35.0B | 100 |
| INSM Insmed | Healthcare | $31.7B | 100 |
| GFI Gold Fields | Basic Materials | $28.9B | 100 |
| NBIS Nebius Group | Communication Services | $28.4B | 100 |
| RGLD Royal Gold | Basic Materials | $19.6B | 100 |
| BG Bunge Global | Consumer Defensive | $17.6B | 100 |
| SMCI Super Micro Computer | Technology | $15.7B | 100 |
| TLN Talen Energy | Utilities | $15.5B | 100 |
| BBIO BridgeBio Pharma | Healthcare | $15.2B | 100 |
| PNFP Pinnacle Financial Partners | Financial Services | $14.4B | 100 |
| CDE Coeur Mining | Basic Materials | $11.8B | 100 |
| QXO QXO | Industrials | $11.5B | 100 |
| EQX Equinox Gold | Basic Materials | $10.6B | 100 |
Lowest Revenue Growth (Quarterly) scores
| Company | Sector | Market cap | Score |
|---|---|---|---|
| CLDX Celldex Therapeutics | Healthcare | $2.2B | 0 |
| AD Array Digital Infrastructure | Communication Services | $2.3B | 0 |
| CALM Cal-Maine Foods | Consumer Defensive | $3.3B | 0 |
| SWX Southwest Gas | Utilities | $6.5B | 0 |
| OPEN Opendoor Technologies | Real Estate | $1.4B | 1 |
| ZBIO Zenas BioPharma | Healthcare | $1.7B | 1 |
| ZYME Zymeworks | Healthcare | $1.9B | 1 |
| RCUS Arcus Biosciences | Healthcare | $2.3B | 1 |
| HTGC Hercules Capital | Financial Services | $2.9B | 1 |
| DNLI Denali Therapeutics | Healthcare | $2.9B | 1 |
One scorer is one input among many, not a recommendation. Each company’s page shows every scorer behind its composite.